# Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

> **NCT01966107** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3635 (actual)

## Conditions studied

- COPD
- Chronic Obstructive Pulmonary Disease
- Moderate to Very Severe COPD

## Interventions

- **DRUG:** Aclidinium Bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01966107
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-16
- **Primary completion:** 2017-09-21
- **Final completion:** 2017-09-21
- **Target enrollment:** 3635 (ACTUAL)
- **Last updated:** 2018-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966107, "Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01966107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*